Skip Navigation
Skip to contents

KMJ : Kosin Medical Journal

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Kosin Med J > Volume 41(3); 2026 > Article
Original article
Effect of stir-fried versus non-stir-fried olive oil in cooked food on erythrocyte membrane fatty acid composition in hemodialysis patients: a randomized controlled trial
Jeong Min Hong1,*orcid, Jin Kyeong Kim1,*orcid, Dong Eun Yang2orcid, Yongsoon Park3orcid, Su Mi Lee2,**orcid, Won Suk An2,**orcid
Kosin Medical Journal 2026;41(3):231-239.
DOI: https://doi.org/10.7180/kmj.26.151
Published online: August 18, 2026

1Department of Internal Medicine, Dong-A University Hospital, Busan, Korea

2Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea

3Department of Food and Nutrition, Hanyang University, Seoul, Korea

Corresponding Author: Su Mi Lee, MD Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan 49201, Korea Tel: +82-51-240-2837 Fax: +82-51-242-5974 E-mail: sumilee@dau.ac.kr
Corresponding Author: Won Suk An, MD Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan 49201, Korea Tel: +82-51-240-2811 Fax: +82-51-242-5852 E-mail: anws@dau.ac.kr
*These authors contributed equally to this work as first authors.
**These authors contributed equally to this work as corresponding authors.
• Received: January 20, 2026   • Revised: March 17, 2026   • Accepted: March 26, 2026

© 2026 Kosin University College of Medicine.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 990 Views
  • 26 Download
  • 2 Crossref
prev next
See the editorial "Effects of olive oil preparation on erythrocyte membrane fatty acid composition and nutritional status in patients receiving hemodialysis" in Volume 41 on page 181.
  • Background
    Individuals receiving maintenance hemodialysis (HD) are at particularly high risk for cardiovascular disease. Although olive oil intake has been associated with cardiovascular benefits, the effects of stir-fried olive oil on erythrocyte membrane fatty acid (FA) composition in patients undergoing HD have not been adequately investigated. This study aimed to compare the effects of stir-fried and non-stir-fried olive oil on changes in erythrocyte membrane FA composition in patients undergoing HD.
  • Methods
    In this single-blind randomized trial, 31 patients undergoing HD received lunch meals containing extra virgin olive oil for 12 weeks. Meals were prepared using one of two methods: the olive oil was either used during stir-frying or added after cooking without heat exposure. Erythrocyte membrane FA profiles were assessed at baseline and after the 12-week intervention using gas chromatography.
  • Results
    A total of 27 participants completed the study. Overall caloric intake and animal-derived lipid intake did not differ between the groups. In the stir-fried olive oil group, erythrocyte membrane trans-oleic acid levels increased significantly after 12 weeks. In contrast, the non-stir-fried olive oil group showed significant increases in saturated FAs, including stearic acid, along with a higher arachidonic acid-to-eicosapentaenoic acid ratio and increased serum albumin levels.
  • Conclusions
    Stir-fried olive oil increased trans-oleic acid levels in erythrocyte membrane FA composition, whereas non-stir-fried olive oil improved serum albumin levels. These findings suggest that preparation methods may be as important as the oil itself, with non-stir-fried olive oil offering a potentially useful nutritional strategy for patients undergoing HD.
Patients with advanced chronic kidney disease (CKD) experience substantially higher mortality than the general population, and cardiovascular disease (CVD) remains the leading cause of death among patients receiving dialysis therapy, accounting for nearly half of all fatalities in this group [1,2]. Despite advances in renal replacement therapy, the burden of cardiovascular complications in patients undergoing hemodialysis (HD) has not been adequately reduced.
Dietary intervention has emerged as an important nonpharmacologic strategy for cardiovascular risk reduction. In the general population, adherence to a Mediterranean dietary pattern has been associated with a reduced incidence of coronary artery disease and improved cardiovascular outcomes [3,4]. This dietary approach emphasizes plant-based foods, olive oil as the primary source of fat, moderate intake of fish and dairy products, and limited consumption of red meat. However, the applicability of this diet to patients with CKD is limited because several components are restricted owing to concerns regarding hyperkalemia, hyperphosphatemia, metabolic acidosis, and disease progression. Food restrictions are stricter in patients undergoing HD than in those undergoing peritoneal dialysis. However, olive oil may be a relatively appropriate food component of the Mediterranean diet for CVD prevention in HD patients.
The fatty acid (FA) composition of erythrocyte membranes reflects long-term dietary lipid intake over approximately 3 months and has been proposed as a surrogate marker of cardiovascular risk. Indices such as the omega-3 index and the ratio of eicosapentaenoic acid (EPA) to arachidonic acid (AA) have been widely investigated in relation to cardiovascular outcomes [5]. Previous studies have reported higher erythrocyte membrane oleic acid levels in patients with acute coronary syndromes compared with healthy controls [6]. In addition, elevated oleic acid levels have been observed in HD patients at increased cardiovascular risk [7,8]. One report showed that oleic acid levels in the erythrocyte membrane were lower in HD patients consuming omega-3 FA than in those taking olive oil [9]. Reductions in erythrocyte membrane oleic acid have also been reported following olive oil supplementation alone, suggesting that adequate olive oil intake within a balanced dietary context may exert effects comparable to omega-3 FA supplementation. While the optimal use of olive oil involves consumption without heating, such as in salads or with bread, many individuals habitually use olive oil for stir-frying instead of conventional cooking oils. However, evidence regarding the effects of olive oil subjected to stir-frying is still limited.
This clinical trial aimed to determine whether consuming meals with olive oil affects erythrocyte membrane FA content, including oleic acid, in HD patients. The differences in FA content were investigated between stir-fried and non-stir-fried olive oils.
Ethical statements: This study was approved by the Institutional Review Board (IRB) of Dong-A University Hospital (IRB No. 15-190), and written informed consent was obtained from all participants. This study was conducted according to the Helsinki Declaration.
1. Study design and participants
This randomized controlled trial was conducted between October 2015 and May 2016 (NCT02993380). This clinical trial aimed to determine significant changes in the erythrocyte membrane FA content before and after olive oil intake in patients undergoing HD. A total of 31 HD patients participated in this study (Fig. 1). Participants were randomized 1:1 into the stir-fried or non-stir-fried olive oil group. The randomization sequence was generated using Research Randomizer (Social Psychology Network). To ensure allocation concealment, an independent researcher managed the sequence. In this single-blind study, the investigators were blinded to group allocation during laboratory analysis and statistical processing. Fifteen patients consumed non-stir-fried olive oil, whereas 16 patients consumed stir-fried olive oil. Adults aged 20‒80 years who had undergone regular HD sessions three times weekly for no less than 6 months were considered eligible. Participants were excluded for the following reasons: use of omega-3 FA supplements within the past 3 months; habitual olive oil consumption exceeding 10 g three times weekly during the same period; recent hospitalization for cardiovascular or infectious diseases; current or planned pregnancy; coexisting liver cirrhosis or malignancy; and serum albumin levels below 3.0 g/dL at baseline.
The total period of olive oil intake was 3 months. Six types of menus were selected with a properly restricted diet for HD patients, and food was supplied as a lunch meal three times per week on the HD day. The menus were rotated biweekly and included commonly served dishes such as mixed vegetable rice, French toast, berry rice, bulgogi rice bowl, squid-beef rice, and Hamburg steak (Supplementary Table 1). In one group, lunch meals were stir-fried in olive oil. In the second group, olive oil was mixed with the meal without stir-frying. Fried rice was prepared by stir-frying with olive oil instead of the standard cooking oil. Participants consumed meals containing fried rice cooked in olive oil. Extra virgin olive oil was added to fried rice, which was cooked in water in a pan without any oil, and mixed with non-stir-fried olive oil before meals. The amount of lunch eaten was assessed, and dietary questionnaire scores were evaluated at baseline and after 12 weeks.
Thirty-one patients were initially enrolled. Among them, four patients dropped out during the trial period: three withdrew consent because the meals did not taste good, and one was transferred to another medical facility. A total of 27 participants completed the intervention. These individuals were comparably allocated between the two study arms, with 14 assigned to meals supplemented with extra virgin olive oil added after cooking, while 13 received meals prepared with olive oil exposed to stir-frying. Dialysis regimens remained unchanged throughout the study, and all participants consumed more than 85% of the provided meals over the 12-week period, supporting adequate dietary adherence for outcome evaluation. The primary outcome was the change in erythrocyte membrane FA composition, including oleic acid, after 12 weeks of consuming lunch meals prepared with non-stir-fried or stir-fried olive oil.
2. Survey of food consumption
Dietary intake was assessed at baseline and 12 weeks using a 121-item semi-quantitative food frequency questionnaire from the Korean Cancer Research Survey. To ensure accurate portion size estimation, we utilized three-dimensional food models and full-scale photographs. Nutrient intake was calculated using the Computer Aided Nutritional Analysis Program (CAN-Pro 3.0; Korean Nutrition Society), which includes a database of 1,823 food items.
3. Laboratory measurements
Blood samples were obtained from each participant before HD. The blood samples were processed, immediately refrigerated, and then stored at −70 °C until analysis. Serum levels of hemoglobin, glucose, glycated hemoglobin, blood urea nitrogen, creatinine, total protein, albumin, calcium, phosphorus, C-reactive protein, total cholesterol, triglyceride, high-density lipoprotein (HDL)-cholesterol, and low-density lipoprotein (LDL)-cholesterol were analyzed using a routine automated machine at Dong-A University Hospital. The body mass index was calculated using weight and height measurements (weight [kg]/height [m2]).
4. Gas chromatography
Isolated erythrocytes were methylated by the addition of boron trifluoride methanol-benzene for 10 minutes at 100 °C. FA methyl esters were analyzed using gas chromatography (Shimadzu 2010 AF; Shimadzu Scientific Instrument) with a 100-m SP2560 capillary column (Supelco). The FA were identified by comparison with known standards (GLC-727; Nu-Chek Prep). The omega-3 index is a measure of EPA and docosahexaenoic acid (DHA) in the erythrocyte membranes. The erythrocyte membrane FA content was expressed as weight percentage.
5. Statistical analyses
In a previous study, the significant mean value of erythrocyte membrane oleic acid changes in dialysis patients with omega-3 supplement was 2.5 weight %, and the standard deviation was 2.0 weight %. It was assumed that the oleic acid level was lower than that in the omega-3–supplemented group; therefore, the effective mean value calculated was 1% weight. A minimum sample size of 31 patients was required to achieve at least 80% power, a two-tailed significance level of 0.05, and a dropout rate of 20%.
Data are presented as the mean±standard deviation or frequency. Characteristics were analyzed using the Mann-Whitney U test. The nonparametric Wilcoxon exact rank sum test was used to compare baseline data with 12-week data, and the chi-square test was used for categorical variables. All analyses were performed using PASW Statistics ver. 18.0 (IBM Corp.), statistical significance was set at p<0.05.
1. Baseline characteristics
The baseline characteristics of the study participants are presented in Table 1. Four patients dropped out, three patients withdrew consent from the group with stir-fried olive oil, and one patient was admitted to another medical center from the group without stir-fried olive oil. The main reason for consent withdrawal was that the meals were tasteless or could not be eaten. Finally, 27 HD patients completed the study, including 14 without stir-fried olive oil group and 13 with stir-fried olive oil group. There were no significant differences in age (58.0±12.1 years vs. 59.1±12.7 years), dialysis duration (62.3±39.4 months vs. 63.4±46.6 months), prevalence of diabetes mellitus (85.7% vs. 53.8%), and baseline laboratory parameters, including lipid profiles. In the overall study population (n=27), ultrafiltration volume decreased modestly from baseline to 12 weeks (2,441±786 mL vs. 2,126±869 mL; p=0.020). The within-group changes were not statistically significant (non-stir-fried group, 2,714±631 to 2,350±964 mL, p=0.11; stir-fried group, 2,146±852 to 1,885±712 mL, p=0.058), and the magnitude of change did not differ between groups (p=0.58). Adherence to the dietary intervention was high, with all participants consuming more than 85% of the provided lunch meals.
2. Diet consumption data
The results of the food consumption surveys are presented in Table 2. There were no significant changes in the total calories or animal lipid components between the groups without stir-fried extra virgin olive oil and with stir-fried extra virgin olive oil. In both groups, there were no significant changes in saturated FA, monounsaturated FA, or polyunsaturated FA after 12 weeks compared to baseline data.
3. Changes in biochemical data
The differences in biochemical measurements between baseline and the 12-week follow-up are presented in Table 3. Serum albumin levels increased significantly after 12 weeks in patients who did not consume stir-fried olive oil (4.0±0.2 g/dL vs. 4.1±0.1 g/dL; p=0.008). In the stir-fried olive oil group, serum glucose levels showed a significant reduction at 12 weeks compared with baseline (145.7±92.5 mg/dL vs. 101.4±56.5 mg/dL; p=0.028). In contrast, no significant changes were observed in total cholesterol, triglyceride, HDL-cholesterol, or LDL-cholesterol over the same period.
4. FA composition of the erythrocyte membrane
Alterations in erythrocyte membrane FA composition are presented in Table 4. Among participants consuming meals prepared with stir-fried olive oil, trans-oleic acid levels increased significantly after 12 weeks compared with baseline (0.25±0.04 vs. 0.34±0.23; p=0.028) (Fig. 2). In contrast, patients receiving meals prepared without stir-frying showed a significant rise in saturated FA content in erythrocyte membranes over the same period (41.4±0.9 vs. 42.1±0.9; p<0.05). In participants consuming meals prepared without stir-fried olive oil, erythrocyte membrane EPA levels declined significantly from baseline (1.6±0.5 to 1.5±1.1; p=0.019), while the AA to EPA ratio (AA/EPA) showed a significant increase (10.0±3.3 vs. 12.4±5.3; p=0.013).
High trans-FA content is associated with inflammation, oxidative stress, and lipoperoxidation, which contribute to the progression of atherosclerosis [10,11]. In the present study, trans-oleic acid levels increased in participants consuming stir-fried olive oil. This increase may be attributed to thermal isomerization, where the heat of stir-frying converts cis-oleic acid into its stable trans-isomer [12]. Although the absolute magnitude of this increase was small, these changes are clinically relevant for end-stage renal disease (ESRD) patients. Even minor accumulation of trans-FAs can exacerbate endothelial dysfunction and proinflammatory signaling in populations with high oxidative stress. Consequently, stir-frying may negate the expected cardioprotective effects of olive oil and could paradoxically increase cardiovascular risk in this population. Furthermore, the antioxidative benefits of olive oil are diminished during heating due to the degradation of phenolic compounds [13]. A previous study demonstrated that antioxidant activity, measured by the 2,2-Diphenyl-1-picrylhydrazyl assay, decreased from 740 μmol Trolox/kg to below 250 μmol Trolox/kg after six frying cycles [14]. Therefore, to preserve nutritional integrity and minimize the formation of harmful trans-FAs, it is recommended to avoid high temperatures stir-frying or to consume olive oil in a non-stir-fried state.
CVD remains the leading cause of morbidity and mortality in patients with CKD and ESRD [15]. A systematic review and meta-analysis involving adults with ESRD reported that the incidence of sudden cardiac death (SCD) ranged from 0.4 to 10.04 events per 100 person-years [16]. This substantial and quantifiable risk highlights the need to reduce modifiable contributors to SCD, including dietary components such as trans-FAs. Accordingly, patients undergoing HD may benefit from avoiding the use of olive oil under high-temperature cooking conditions to mitigate potential cardiovascular harm. Although this study was conducted in 2015‒2016, it provides practical evidence for managing olive oil-based diets in HD patients. While olive oil is recommended for HD patients, guidelines rarely specify cooking methods. Our findings show that preparation methods influence FA composition, providing a basis for improved dietary guidance in HD patients.
In this study, we hypothesized that olive oil intake would increase erythrocyte membrane omega-3 content. Prior studies showed that Mediterranean diets, especially those incorporating extra virgin olive oil, correlate with favorable cardiovascular outcomes and higher omega-3 indices, including EPA, DHA, and the AA/EPA ratio [17]. Consistent with these observations, our previous work showed elevations in omega-3 levels following combined omega-3 and olive oil supplementation. Additionally, an experimental study reported increased omega-3 levels in rats fed an olive oil enriched diet [18].
However, this study found that erythrocyte EPA content significantly decreased and the AA/EPA ratio significantly increased, although the total omega-3 FA content remained unchanged. These findings were particularly significant in the non-stir-fried olive oil group. One potential mechanism involves competition between omega-3 and omega-6 FAs for the same delta-5 and delta-6 desaturase enzymes. Since olive oil is rich in omega-9 but lacks EPA, its supplementation may lead to a relative accumulation of AA. While olive oil consumption is generally inversely associated with CVD risk, our results suggest that 30 g/week is insufficient to increase EPA or lower the AA/EPA ratio in HD patients. Further studies are needed to determine whether higher doses, such as the 20 g/day [19], or extending durations can modify the erythrocyte membrane FA composition.
Notably, participants consuming non-stir-fried olive oil exhibited an increase in serum albumin at 12 weeks. This improvement may be attributed to several factors. First, the energy source from olive oil may offer a protein-sparing effect, allowing amino acids to be utilized for albumin synthesis instead of energy production. Second, preserved antioxidants in non-stir-fried oil may mitigate inflammation, supporting hepatic albumin synthesis. Third, the increase may reflect the overall nutritional support provided by the standardized lunch boxes rather than a specific effect of oil preparation. Therefore, this finding remains preliminary and warrants further investigation in larger studies to identify the specific impact of olive oil. Patients undergoing long-term dialysis are susceptible to protein-energy wasting, which is linked to increased morbidity and mortality [20,21]. The 12-week distribution of tailored lunch boxes demonstrates a practical and effective approach for enhancing nutritional intake and improving patient prognosis.
Several limitations of this study should be acknowledged. First, the small sample size and short duration limit statistical power, increasing the risk of type II error. Negative findings, such as the omega-3 index, may reflect insufficient power to detect subtle changes in FA composition rather than a definitive absence of effect. Second, as only lunch was standardized, uncontrolled intake during other meals potentially introduced confounding. This background diet may have masked the intervention’s effects and contributed to variability in markers such as glucose. Specifically, the glucose decrease observed in the stir-fried group may be attributed to dietary variability rather than a direct effect of olive oil. Larger studies with strict dietary monitoring are needed to confirm these findings.
In conclusion, 30 g/week of olive oil was insufficient to improve erythrocyte membrane FA composition in HD patients. Stir-fried olive oil may induce trans-oleic acid, compromising its potential cardiovascular benefits, whereas non-stir-fried olive oil improved serum albumin. These findings suggest that the method of preparation is as important as the oil itself, with non-stir-fried olive oil offering a practical nutritional strategy to enhance the prognosis of patients on HD.
Supplementary materials are available at https://doi.org/10.7180/kmj.26.151.
Supplementary Table 1.
Lunch menus and ingredients provided during the study
kmj-26-151-Supplementary-Table-1.pdf

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

None.

Author contributions

Conceptualization: WSA. Data curation: JMH, JKK, SML, WSA. Formal analysis: SML, WSA. Investigation: YP, SML, WSA. Methodology: SML, WSA. Project administration: SML, WSA. Resources: SML, WSA. Software: SML, WSA. Supervision: SML, WSA. Validation: DEY, SML. Visualization: JMH, JKK. Writing-original draft: JMH, JKK. Writing-review & editing: JMH, JKK, DEY, YP, SML, WSA. All authors have read and approved the final manuscript.

Fig. 1.
Flow diagram of patient selection.
kmj-26-151f1.jpg
Fig. 2.
Comparison of trans-oleic acid levels at baseline and after 12 weeks in non-stir-fried and stir-fried olive oil groups.
*p<0.05 (mean values are significantly different from baseline).
FA, fatty acid.
kmj-26-151f2.jpg
Table 1.
Clinical blood biochemical analyses of the participants
Variable Non-stir-fried olive oil  (n=14) Stir-fried olive oil (n=13) p-valuea)
Age (yr) 58.0±12.1 59.1±12.7 0.662
Male sex 7 (50.0) 5 (38.5) 0.547
Diabetes mellitus 12 (85.7) 7 (53.8) 0.070
Duration of dialysis (mo) 62.3±39.4 63.4±46.6 0.903
Ultrafiltration volume (mL) 2,714±631 2,146±852 0.068
Amount of intake 0.87±0.13 0.85±0.18 0.922
Body mass index (kg/m2) 22.7±3.6 21.5±2.9 0.344
Glucose (mg/dL) 163.6±150.8 145.7±92.5 0.680
HbA1c (%) 8.3±1.5 9.4±2.8 0.472
Hemoglobin (g/dL) 10.9±1.0 11.3±1.0 0.319
Calcium (mg/dL) 9.1±0.6 9.3±0.6 0.662
Phosphorus (mg/dL) 5.1±1.3 5.2±1.3 0.808
BUN (mg/dL) 65.6±20.9 73.7±16.3 0.296
Creatinine (mg/dL) 11.4±3.0 11.5±1.9 0.560
GFR (mL/min/1.73 m2) 4.6±1.3 4.1±0.5 0.368
Total protein (g/dL) 7.3±0.5 7.2±0.6 0.752
Albumin (g/dL) 4.0±0.2 3.9±0.3 0.572
Total cholesterol (mg/dL) 162.5±60.7 163.4±45.9 0.577
Triglyceride (mg/dL) 259.4±273.2 168.5±104.1 0.382
HDL (mg/dL) 40.2±10.9 43.1±10.9 0.496
LDL (mg/dL) 84.0±38.6 99.5±41.9 0.132
CRP (mg/dL) 0.5±1.0 0.4±0.5 0.593

Values are presented as mean±standard deviation or number (%).

HbA1c, glycated hemoglobin; BUN, blood urea nitrogen; GFR, glomerular filtration rate; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; CRP, C-reactive protein.

a)p-value for the nonparametric Mann-Whitney U test comparing baseline data between two groups. The difference in frequency was tested using Pearson X2.

Table 2.
Dietary consumption of foods and nutrients
Variable Non-stir-fried olive oil (n=14) Stir-fried olive oil (n=13)
Baseline 12 wk Baseline 12 wk
Kcal (kcal) 1,173.4±466.3 1,150.4±1,321.9 1,328.9±499.1 1,321.9±559.9
Animal protein (g) 17.3±12.0 15.7±13.4 17.6±12.7 15.7±9.7
Vegetable protein (g) 19.3±7.3 18.5±7.0 23.8±9.6 22.8±9.5
Animal lipids (g) 12.0±9.3 10.1±10.0 10.5±5.4 10.5±6.3
Vegetable lipids (g) 8.7±5.1 9.1±10.2 11.9±6.4 9.0±5.0
Carbohydrate (g) 209.9±71.8 209.1±72.4 241.9±91.1 245.9±103.8
Fiber (g) 9.6±4.0 12.7±6.8 8.7±3.3 9.9±4.5
Retinol (μg) 84.6±69.9 93.4±146.3 84.0±47.2 83.4±58.4
Niacin (mg) 6.7±3.2 6.0±2.7 7.7±3.8 6.9±3.4
Vitamin E (mg) 7.0±4.2 7.2±7.4 8.9±4.7 7.2±4.0
Cholesterol (mg) 190.9±152.8 238.1±447.2 245.9±172.0 222.1±173.7
Saturated FA (g) 5.5±4.9 4.2±2.2 4.7±4.2 4.2±2.6
Monounsaturated FA (g) 5.7±5.0 4.9±3.1 5.5±5.9 4.8±3.2
Polyunsaturated FA (g) 3.6±2.8 4.3±2.6 4.0±5.3 3.6±2.3

Values are presented as mean±standard deviation. The nonparametric Wilcoxon exact rank sum test was used to compare baseline data with 12-week data.

FA, fatty acid.

Table 3.
Changes in biochemical data
Variable Non-stir-fried olive oil (n=14) Stir-fried olive oil (n=13)
Baseline 12 wk Baseline 12 wk
Body mass index (kg/m2) 22.7±3.6 22.6±3.5 21.5±2.9 21.3±3.0
Glucose (mg/dL) 163.6±150.8 175.3±109.4 145.7±92.5 101.4±56.5a)
HbA1c (%) 8.3±1.5 8.2±1.2 9.4±2.8 8.2±2.0
Hemoglobin (g/dL) 10.9±1.0 10.9±1.2 11.3±1.0 10.8±1.1
Calcium (mg/dL) 9.1±0.6 9.1±0.5 9.3±0.6 9.3±0.8
Phosphorus (mg/dL) 5.1±1.3 5.6±0.6 5.2±1.3 5.1±1.6
BUN (mg/dL) 65.6±20.9 77.6±19.5 73.7±16.3 69.0±19.0
Creatinine (mg/dL) 11.4±3.0 11.8±3.2 11.5±1.9 11.3±2.2
GFR (mL/min/1.73 m2) 4.6±1.3 4.4±1.0 4.1±0.5 4.3±0.6
Total protein (g/dL) 7.3±0.5 7.5±0.6 7.2±0.6 7.3±0.7
Albumin (g/dL) 4.0±0.2 4.1±0.1a) 3.9±0.3 4.0±0.4
Total cholesterol (mg/dL) 162.5±60.7 153.2±43.5 163.4±45.9 152.7±43.3
Triglyceride (mg/dL) 259.4±273.2 185.6±124.2 168.5±104.1 139.5±90.1
HDL (mg/dL) 40.2±10.9 38.0±10.5 43.1±10.9 42.8±11.8
LDL (mg/dL) 84.0±38.6 86.2±39.0 99.5±41.9 87.8±34.4
CRP (mg/dL) 0.5±1.0 0.6±0.6 0.4±0.5 1.7±4.2

Values are presented as mean±standard deviation. The nonparametric Wilcoxon exact rank sum test was used to compare baseline data with 12-week data.

HbA1c, glycated hemoglobin; BUN, blood urea nitrogen; GFR, glomerular filtration rate; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; CRP, C-reactive protein.

a)p<0.05 (mean values are significantly different from baseline).

Table 4.
Changes in erythrocyte membrane fatty acid content
Variable  Total (baseline) Total (12 wk) Non-stir-fried olive oil (n=14) Stir-fried olive oil (n=13)
Baseline 12 wk Baseline 12 wk
Saturated 41.4±0.8 41.9±1.0a) 41.4±0.9 42.1±0.9a) 41.3±0.6 41.7±1.2
 Myristic 0.28±0.08 0.26±0.09 0.31±0.09 0.27±0.09 0.24±0.06 0.25±0.08
 Palmitic 22.8±1.3 22.7±1.2 23.0±1.4 22.7±1.1 22.5±1.0 22.8±1.4
 Stearic 18.1±0.9 18.7±0.9a) 17.9±0.9 18.9±1.2a) 18.3±0.9 18.6±0.6
 Lignoceric 0.22±0.05 0.19±0.07 0.21±0.05 0.19±0.05 0.22±0.05 0.19±0.08
Monounsaturated 15.5±0.8 15.2±1.1 15.7±0.9 15.2±1.2 15.3±0.8 15.2±0.9
 Palmitoleic 0.41±0.20 0.36±0.14 0.44±0.24 0.35±0.16 0.39±0.16 0.36±0.12
 Oleic 14.5±0.7 14.4±0.9 14.7±0.7 14.4±1.0 14.4±0.7 14.4±0.9
Polyunsaturated 42.6±1.2 42.3±1.4 42.3±1.3 42.1±1.4 42.8±1.1 42.4±1.5
 Omega-6 29.3±2.2 29.1±2.4 28.7±2.2 28.8±2.3 29.9±2.1 30.0±2.4
  Linoleic 9.6±1.4 9.0±1.4a) 9.5±1.4 8.9±1.3 9.7±1.3 9.1±1.5
  AA 14.5±1.6 14.8±1.5 14.3±1.8 14.8±1.6 14.8±1.5 14.9±1.5
 Omega-3 13.3±2.1 13.1±2.5 13.6±1.9 13.4±2.3 12.9±2.3 12.9±2.7
  Alpha-linolenic 0.17±0.08 0.14±0.07a) 0.19±0.10 0.16±0.08 0.15±0.04 0.13±0.06
  EPA 1.5±0.6 1.4±1.0a) 1.6±0.5 1.5±1.1a) 1.4±0.6 1.2±0.8
  DHA 8.4±1.4 8.3±1.4 8.4±1.2 8.4±1.3 8.3±1.6 8.2±1.6
Omega-3 index 9.9±1.8 9.7±2.1 10.0±1.5 9.9±2.0 9.7±2.1 9.4±2.2
AA/EPA 11.7±6.5 14.3±6.8a) 10.0±3.3 12.4±5.3a) 13.6±8.6 16.2±7.9
Omega-6/Omega-3 2.3±0.6 2.3±0.6 2.2±0.5 2.2±0.5 2.4±0.7 2.4±0.7
Total trans-fatty acid 0.56±0.07 0.61±0.20 0.56±0.08 0.57±0.10 0.56±0.06 0.65±0.26
 Trans-palmitoleic acid 0.15±0.03 0.14±0.03 0.16±0.02 0.14±0.03 0.14±0.03b) 0.14±0.03
 Trans-oleic acid 0.25±0.06 0.30±0.17a) 0.24±0.07 0.25±0.05 0.25±0.04 0.34±0.23a)
 Trans-linoleic acid 0.17±0.03 0.17±0.04 0.16±0.03 0.17±0.04 0.17±0.03 0.17±0.04
  18:2n6tt 0.02±0.01 0.01±0.02 0.02±0.01 0.01±0.00 0.02±0.01 0.02±0.03
  18:2n6ct 0.05±0.01 0.05±0.02 0.05±0.01 0.05±0.02 0.05±0.01 0.05±0.03
  18:2n6tc 0.10±0.02 0.10±0.02 0.10±0.02 0.11±0.03 0.10±0.02 0.10±0.02

Values are presented as mean±standard deviation. The nonparametric Wilcoxon exact rank sum test was used to compare baseline data with 12-week data.

a)p<0.05 (mean values are significantly different from baseline). b)p<0.05 (mean values are significantly different from those of non-stir-fried olive oil).

AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.

  • 1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112–9.Article
  • 2. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659–63.ArticlePubMed
  • 3. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol 1986;124:903–15.ArticlePubMed
  • 4. Martinez-Gonzalez MA, Salas-Salvado J, Estruch R, Corella D, Fito M, Ros E. Benefits of the Mediterranean diet: insights from the PREDIMED study. Prog Cardiovasc Dis 2015;58:50–60.ArticlePubMed
  • 5. Lee SM, Son YK, Kim SE, An WS. The effects of omega-3 fatty acid on vitamin D activation in hemodialysis patients: a pilot study. Mar Drugs 2015;13:741–55.ArticlePubMedPMC
  • 6. Lee SM, Chung SH, Park Y, Park MK, Son YK, Kim SE, et al. Effect of omega-3 fatty acid on the fatty acid content of the erythrocyte membrane and proteinuria in patients with diabetic nephropathy. Int J Endocrinol 2015;2015:208121.ArticlePubMedPMCPDF
  • 7. An WS, Lee SM, Son YK, Kim SE, Kim KH, Han JY, et al. Effect of omega-3 fatty acids on the modification of erythrocyte membrane fatty acid content including oleic acid in peritoneal dialysis patients. Prostaglandins Leukot Essent Fatty Acids 2012;86:29–34.ArticlePubMed
  • 8. An WS, Lee SM, Son YK, Kim SE, Kim KH, Han JY, et al. Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin: a levels in dialysis patients. Nutr Res 2012;32:495–502.ArticlePubMed
  • 9. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003;107:2646–52.ArticlePubMed
  • 10. Hadj Ahmed S, Kharroubi W, Kaoubaa N, Zarrouk A, Batbout F, Gamra H, et al. Correlation of trans fatty acids with the severity of coronary artery disease lesions. Lipids Health Dis 2018;17:52.ArticlePubMedPMC
  • 11. Nykiel S, Misiuk J, Kopec K, Bartoszek A, Adamiuk J, Marut A, et al. The dietary fats: a comprehensive study about the influence of different types of fats on general health and developing diseases. Qual Sport 2025;40:58799.ArticlePDF
  • 12. Cheng N, Zhang J, Yin J, Li S. Computational and experimental research on mechanism of cis/trans isomerization of oleic acid. Heliyon 2018;4:e00768.ArticlePubMedPMC
  • 13. Casal S, Malheiro R, Sendas A, Oliveira BP, Pereira JA. Olive oil stability under deep-frying conditions. Food Chem Toxicol 2010;48:2972–9.ArticlePubMed
  • 14. Gomez-Alonso S, Fregapane G, Salvador MD, Gordon MH. Changes in phenolic composition and antioxidant activity of virgin olive oil during frying. J Agric Food Chem 2003;51:667–72.ArticlePubMed
  • 15. Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res 2023;119:2017–32.ArticlePubMedPMCPDF
  • 16. Ramesh S, Zalucky A, Hemmelgarn BR, Roberts DJ, Ahmed SB, Wilton SB, et al. Incidence of sudden cardiac death in adults with end-stage renal disease: a systematic review and meta-analysis. BMC Nephrol 2016;17:78.ArticlePubMedPMC
  • 17. Sala-Vila A, Harris WS, Cofan M, Perez-Heras AM, Pinto X, Lamuela-Raventos RM, et al. Determinants of the omega-3 index in a Mediterranean population at increased risk for CHD. Br J Nutr 2011;106:425–31.ArticlePubMed
  • 18. Navarro MD, Periago JL, Pita ML, Hortelano P. The n-3 polyunsaturated fatty acid levels in rat tissue lipids increase in response to dietary olive oil relative to sunflower oil. Lipids 1994;29:845–9.ArticlePubMed
  • 19. Xia M, Zhong Y, Peng Y, Qian C. Olive oil consumption and risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies. Front Nutr 2022;9:1041203.ArticlePubMedPMC
  • 20. Marckmann P. Nutritional status and mortality of patients in regular dialysis therapy. J Intern Med 1989;226:429–32.ArticlePubMed
  • 21. Kang SS, Chang JW, Park Y. Nutritional status predicts 10-year mortality in patients with end-stage renal disease on hemodialysis. Nutrients 2017;9:399.ArticlePubMedPMC

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Effects of olive oil preparation on erythrocyte membrane fatty acid composition and nutritional status in patients receiving hemodialysis
      Ho Sik Shin
      Kosin Medical Journal.2026; 41(3): 181.     CrossRef
    • Declining Kidney Function Is Associated with Altered Erythrocyte Membrane Fatty Acid Profiles and Estimated Enzymatic Indices
      Jin Kyeong Kim, Dong Eun Yang, Seong Eun Kim, Won Suk An, Su Mi Lee
      Membranes.2026; 16(10): 342.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy
      Close
    • Download Citation
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Effect of stir-fried versus non-stir-fried olive oil in cooked food on erythrocyte membrane fatty acid composition in hemodialysis patients: a randomized controlled trial
      Kosin Med J. 2026;41(3):231-239.   Published online August 18, 2026
      Close
    • XML DownloadXML Download
    Figure
    • 0
    • 1
    Related articles
    Effect of stir-fried versus non-stir-fried olive oil in cooked food on erythrocyte membrane fatty acid composition in hemodialysis patients: a randomized controlled trial
    Image Image
    Fig. 1. Flow diagram of patient selection.
    Fig. 2. Comparison of trans-oleic acid levels at baseline and after 12 weeks in non-stir-fried and stir-fried olive oil groups.*p<0.05 (mean values are significantly different from baseline).FA, fatty acid.
    Effect of stir-fried versus non-stir-fried olive oil in cooked food on erythrocyte membrane fatty acid composition in hemodialysis patients: a randomized controlled trial
    Variable Non-stir-fried olive oil  (n=14) Stir-fried olive oil (n=13) p-valuea)
    Age (yr) 58.0±12.1 59.1±12.7 0.662
    Male sex 7 (50.0) 5 (38.5) 0.547
    Diabetes mellitus 12 (85.7) 7 (53.8) 0.070
    Duration of dialysis (mo) 62.3±39.4 63.4±46.6 0.903
    Ultrafiltration volume (mL) 2,714±631 2,146±852 0.068
    Amount of intake 0.87±0.13 0.85±0.18 0.922
    Body mass index (kg/m2) 22.7±3.6 21.5±2.9 0.344
    Glucose (mg/dL) 163.6±150.8 145.7±92.5 0.680
    HbA1c (%) 8.3±1.5 9.4±2.8 0.472
    Hemoglobin (g/dL) 10.9±1.0 11.3±1.0 0.319
    Calcium (mg/dL) 9.1±0.6 9.3±0.6 0.662
    Phosphorus (mg/dL) 5.1±1.3 5.2±1.3 0.808
    BUN (mg/dL) 65.6±20.9 73.7±16.3 0.296
    Creatinine (mg/dL) 11.4±3.0 11.5±1.9 0.560
    GFR (mL/min/1.73 m2) 4.6±1.3 4.1±0.5 0.368
    Total protein (g/dL) 7.3±0.5 7.2±0.6 0.752
    Albumin (g/dL) 4.0±0.2 3.9±0.3 0.572
    Total cholesterol (mg/dL) 162.5±60.7 163.4±45.9 0.577
    Triglyceride (mg/dL) 259.4±273.2 168.5±104.1 0.382
    HDL (mg/dL) 40.2±10.9 43.1±10.9 0.496
    LDL (mg/dL) 84.0±38.6 99.5±41.9 0.132
    CRP (mg/dL) 0.5±1.0 0.4±0.5 0.593
    Variable Non-stir-fried olive oil (n=14) Stir-fried olive oil (n=13)
    Baseline 12 wk Baseline 12 wk
    Kcal (kcal) 1,173.4±466.3 1,150.4±1,321.9 1,328.9±499.1 1,321.9±559.9
    Animal protein (g) 17.3±12.0 15.7±13.4 17.6±12.7 15.7±9.7
    Vegetable protein (g) 19.3±7.3 18.5±7.0 23.8±9.6 22.8±9.5
    Animal lipids (g) 12.0±9.3 10.1±10.0 10.5±5.4 10.5±6.3
    Vegetable lipids (g) 8.7±5.1 9.1±10.2 11.9±6.4 9.0±5.0
    Carbohydrate (g) 209.9±71.8 209.1±72.4 241.9±91.1 245.9±103.8
    Fiber (g) 9.6±4.0 12.7±6.8 8.7±3.3 9.9±4.5
    Retinol (μg) 84.6±69.9 93.4±146.3 84.0±47.2 83.4±58.4
    Niacin (mg) 6.7±3.2 6.0±2.7 7.7±3.8 6.9±3.4
    Vitamin E (mg) 7.0±4.2 7.2±7.4 8.9±4.7 7.2±4.0
    Cholesterol (mg) 190.9±152.8 238.1±447.2 245.9±172.0 222.1±173.7
    Saturated FA (g) 5.5±4.9 4.2±2.2 4.7±4.2 4.2±2.6
    Monounsaturated FA (g) 5.7±5.0 4.9±3.1 5.5±5.9 4.8±3.2
    Polyunsaturated FA (g) 3.6±2.8 4.3±2.6 4.0±5.3 3.6±2.3
    Variable Non-stir-fried olive oil (n=14) Stir-fried olive oil (n=13)
    Baseline 12 wk Baseline 12 wk
    Body mass index (kg/m2) 22.7±3.6 22.6±3.5 21.5±2.9 21.3±3.0
    Glucose (mg/dL) 163.6±150.8 175.3±109.4 145.7±92.5 101.4±56.5a)
    HbA1c (%) 8.3±1.5 8.2±1.2 9.4±2.8 8.2±2.0
    Hemoglobin (g/dL) 10.9±1.0 10.9±1.2 11.3±1.0 10.8±1.1
    Calcium (mg/dL) 9.1±0.6 9.1±0.5 9.3±0.6 9.3±0.8
    Phosphorus (mg/dL) 5.1±1.3 5.6±0.6 5.2±1.3 5.1±1.6
    BUN (mg/dL) 65.6±20.9 77.6±19.5 73.7±16.3 69.0±19.0
    Creatinine (mg/dL) 11.4±3.0 11.8±3.2 11.5±1.9 11.3±2.2
    GFR (mL/min/1.73 m2) 4.6±1.3 4.4±1.0 4.1±0.5 4.3±0.6
    Total protein (g/dL) 7.3±0.5 7.5±0.6 7.2±0.6 7.3±0.7
    Albumin (g/dL) 4.0±0.2 4.1±0.1a) 3.9±0.3 4.0±0.4
    Total cholesterol (mg/dL) 162.5±60.7 153.2±43.5 163.4±45.9 152.7±43.3
    Triglyceride (mg/dL) 259.4±273.2 185.6±124.2 168.5±104.1 139.5±90.1
    HDL (mg/dL) 40.2±10.9 38.0±10.5 43.1±10.9 42.8±11.8
    LDL (mg/dL) 84.0±38.6 86.2±39.0 99.5±41.9 87.8±34.4
    CRP (mg/dL) 0.5±1.0 0.6±0.6 0.4±0.5 1.7±4.2
    Variable  Total (baseline) Total (12 wk) Non-stir-fried olive oil (n=14) Stir-fried olive oil (n=13)
    Baseline 12 wk Baseline 12 wk
    Saturated 41.4±0.8 41.9±1.0a) 41.4±0.9 42.1±0.9a) 41.3±0.6 41.7±1.2
     Myristic 0.28±0.08 0.26±0.09 0.31±0.09 0.27±0.09 0.24±0.06 0.25±0.08
     Palmitic 22.8±1.3 22.7±1.2 23.0±1.4 22.7±1.1 22.5±1.0 22.8±1.4
     Stearic 18.1±0.9 18.7±0.9a) 17.9±0.9 18.9±1.2a) 18.3±0.9 18.6±0.6
     Lignoceric 0.22±0.05 0.19±0.07 0.21±0.05 0.19±0.05 0.22±0.05 0.19±0.08
    Monounsaturated 15.5±0.8 15.2±1.1 15.7±0.9 15.2±1.2 15.3±0.8 15.2±0.9
     Palmitoleic 0.41±0.20 0.36±0.14 0.44±0.24 0.35±0.16 0.39±0.16 0.36±0.12
     Oleic 14.5±0.7 14.4±0.9 14.7±0.7 14.4±1.0 14.4±0.7 14.4±0.9
    Polyunsaturated 42.6±1.2 42.3±1.4 42.3±1.3 42.1±1.4 42.8±1.1 42.4±1.5
     Omega-6 29.3±2.2 29.1±2.4 28.7±2.2 28.8±2.3 29.9±2.1 30.0±2.4
      Linoleic 9.6±1.4 9.0±1.4a) 9.5±1.4 8.9±1.3 9.7±1.3 9.1±1.5
      AA 14.5±1.6 14.8±1.5 14.3±1.8 14.8±1.6 14.8±1.5 14.9±1.5
     Omega-3 13.3±2.1 13.1±2.5 13.6±1.9 13.4±2.3 12.9±2.3 12.9±2.7
      Alpha-linolenic 0.17±0.08 0.14±0.07a) 0.19±0.10 0.16±0.08 0.15±0.04 0.13±0.06
      EPA 1.5±0.6 1.4±1.0a) 1.6±0.5 1.5±1.1a) 1.4±0.6 1.2±0.8
      DHA 8.4±1.4 8.3±1.4 8.4±1.2 8.4±1.3 8.3±1.6 8.2±1.6
    Omega-3 index 9.9±1.8 9.7±2.1 10.0±1.5 9.9±2.0 9.7±2.1 9.4±2.2
    AA/EPA 11.7±6.5 14.3±6.8a) 10.0±3.3 12.4±5.3a) 13.6±8.6 16.2±7.9
    Omega-6/Omega-3 2.3±0.6 2.3±0.6 2.2±0.5 2.2±0.5 2.4±0.7 2.4±0.7
    Total trans-fatty acid 0.56±0.07 0.61±0.20 0.56±0.08 0.57±0.10 0.56±0.06 0.65±0.26
     Trans-palmitoleic acid 0.15±0.03 0.14±0.03 0.16±0.02 0.14±0.03 0.14±0.03b) 0.14±0.03
     Trans-oleic acid 0.25±0.06 0.30±0.17a) 0.24±0.07 0.25±0.05 0.25±0.04 0.34±0.23a)
     Trans-linoleic acid 0.17±0.03 0.17±0.04 0.16±0.03 0.17±0.04 0.17±0.03 0.17±0.04
      18:2n6tt 0.02±0.01 0.01±0.02 0.02±0.01 0.01±0.00 0.02±0.01 0.02±0.03
      18:2n6ct 0.05±0.01 0.05±0.02 0.05±0.01 0.05±0.02 0.05±0.01 0.05±0.03
      18:2n6tc 0.10±0.02 0.10±0.02 0.10±0.02 0.11±0.03 0.10±0.02 0.10±0.02
    Table 1. Clinical blood biochemical analyses of the participants

    Values are presented as mean±standard deviation or number (%).

    HbA1c, glycated hemoglobin; BUN, blood urea nitrogen; GFR, glomerular filtration rate; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; CRP, C-reactive protein.

    p-value for the nonparametric Mann-Whitney U test comparing baseline data between two groups. The difference in frequency was tested using Pearson X2.

    Table 2. Dietary consumption of foods and nutrients

    Values are presented as mean±standard deviation. The nonparametric Wilcoxon exact rank sum test was used to compare baseline data with 12-week data.

    FA, fatty acid.

    Table 3. Changes in biochemical data

    Values are presented as mean±standard deviation. The nonparametric Wilcoxon exact rank sum test was used to compare baseline data with 12-week data.

    HbA1c, glycated hemoglobin; BUN, blood urea nitrogen; GFR, glomerular filtration rate; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; CRP, C-reactive protein.

    p<0.05 (mean values are significantly different from baseline).

    Table 4. Changes in erythrocyte membrane fatty acid content

    Values are presented as mean±standard deviation. The nonparametric Wilcoxon exact rank sum test was used to compare baseline data with 12-week data.

    a)p<0.05 (mean values are significantly different from baseline). b)p<0.05 (mean values are significantly different from those of non-stir-fried olive oil).

    AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.


    KMJ : Kosin Medical Journal
    TOP